Brainstorm Cell Therapeutics Inc (BCLI) - Net Assets
Based on the latest financial reports, Brainstorm Cell Therapeutics Inc (BCLI) has net assets worth $822.00K USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($872.00K) and total liabilities ($50.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Brainstorm Cell Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $822.00K |
| % of Total Assets | 94.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -121.89% |
| 10-Year Change | -154.95% |
| Growth Volatility | 343.86 |
Brainstorm Cell Therapeutics Inc - Net Assets Trend (2001–2024)
This chart illustrates how Brainstorm Cell Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Brainstorm Cell Therapeutics Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Brainstorm Cell Therapeutics Inc (2001–2024)
The table below shows the annual net assets of Brainstorm Cell Therapeutics Inc from 2001 to 2024. For live valuation and market cap data, see Brainstorm Cell Therapeutics Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-7.76 Million | -59.82% |
| 2023-12-31 | $-4.86 Million | -61.13% |
| 2022-12-31 | $-3.02 Million | -115.59% |
| 2021-12-31 | $19.34 Million | -45.46% |
| 2020-12-31 | $35.46 Million | +390.14% |
| 2019-12-31 | $-12.22 Million | -343.68% |
| 2018-12-31 | $5.02 Million | -14.69% |
| 2017-12-31 | $5.88 Million | -40.62% |
| 2016-12-31 | $9.90 Million | -29.91% |
| 2015-12-31 | $14.13 Million | +111.66% |
| 2014-12-31 | $6.67 Million | +143.70% |
| 2013-12-31 | $2.74 Million | -34.06% |
| 2012-12-31 | $4.15 Million | +179.17% |
| 2011-12-31 | $1.49 Million | +424.18% |
| 2010-12-31 | $-459.00K | +73.67% |
| 2009-12-31 | $-1.74 Million | +16.04% |
| 2008-12-31 | $-2.08 Million | +14.50% |
| 2007-12-31 | $-2.43 Million | -33.72% |
| 2006-12-31 | $-1.82 Million | +77.05% |
| 2005-12-31 | $-7.91 Million | -1222.96% |
| 2004-12-31 | $704.45K | +2340.84% |
| 2003-12-31 | $-31.44K | -254.42% |
| 2002-12-31 | $20.36K | -60.97% |
| 2001-12-31 | $52.16K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Brainstorm Cell Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22659341400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.00K | % |
| Other Components | $218.86 Million | % |
| Total Equity | $-7.76 Million | 100.00% |
Brainstorm Cell Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Brainstorm Cell Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FUTURE METALS NL
F:3R10
|
$7.28 Million |
|
Anmol India Limited
NSE:ANMOL
|
$7.29 Million |
|
Dr. Martens PLC
LSE:DOCS
|
$7.29 Million |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
$7.29 Million |
|
Dhruv Consultancy Services Limited
NSE:DHRUV
|
$7.28 Million |
|
Koba Resources Ltd
AU:KOB
|
$7.28 Million |
|
UNITH LTD.
F:CM30
|
$7.27 Million |
|
Clever Group Corp
VN:ADG
|
$7.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Brainstorm Cell Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,858,000 to -7,764,000, a change of -2,906,000.
- Net income of 11,623,000 contributed positively to equity growth.
- New share issuances of 7,967,000 increased equity.
- Other factors decreased equity by 22,496,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $11.62 Million | +149.7% |
| Share Issuances | $7.97 Million | +102.61% |
| Other Changes | $-22.50 Million | -289.75% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Brainstorm Cell Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $0.58 | $0.66 | x |
| 2002-12-31 | $0.02 | $0.66 | x |
| 2003-12-31 | $-0.03 | $0.66 | x |
| 2004-12-31 | $0.57 | $0.66 | x |
| 2005-12-31 | $-80.86 | $0.66 | x |
| 2006-12-31 | $-1.15 | $0.66 | x |
| 2007-12-31 | $-1.24 | $0.66 | x |
| 2008-12-31 | $-0.63 | $0.66 | x |
| 2009-12-31 | $-0.43 | $0.66 | x |
| 2010-12-31 | $-0.08 | $0.66 | x |
| 2011-12-31 | $0.19 | $0.66 | x |
| 2012-12-31 | $6.51 | $0.66 | x |
| 2013-12-31 | $0.26 | $0.66 | x |
| 2014-12-31 | $6.00 | $0.66 | x |
| 2015-12-31 | $11.45 | $0.66 | x |
| 2016-12-31 | $7.95 | $0.66 | x |
| 2017-12-31 | $4.65 | $0.66 | x |
| 2018-12-31 | $3.61 | $0.66 | x |
| 2019-12-31 | $-7.17 | $0.66 | x |
| 2020-12-31 | $15.71 | $0.66 | x |
| 2021-12-31 | $7.98 | $0.66 | x |
| 2022-12-31 | $-1.23 | $0.66 | x |
| 2023-12-31 | $-1.27 | $0.66 | x |
| 2024-12-31 | $-1.46 | $0.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Brainstorm Cell Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1369.02%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-179.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -49.00% | -111.62% | 0.36x | 1.22x | $-30.78K |
| 2002 | -229.91% | -56.47% | 1.82x | 2.23x | $-48.84K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-70.15K |
| 2004 | -2674.39% | 0.00% | 0.00x | 1.25x | $-18.91 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.53 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.74 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.00 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.26 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.61 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.37 Million |
| 2011 | -263.31% | 0.00% | 0.00x | 1.84x | $-4.07 Million |
| 2012 | -86.14% | 0.00% | 0.00x | 1.33x | $-3.83 Million |
| 2013 | -178.86% | 0.00% | 0.00x | 1.73x | $-5.17 Million |
| 2014 | -138.52% | 0.00% | 0.00x | 1.48x | $-9.91 Million |
| 2015 | -60.08% | 0.00% | 0.00x | 1.21x | $-9.90 Million |
| 2016 | -50.31% | 0.00% | 0.00x | 1.09x | $-5.97 Million |
| 2017 | -84.22% | 0.00% | 0.00x | 1.94x | $-5.54 Million |
| 2018 | -278.07% | 0.00% | 0.00x | 2.24x | $-14.45 Million |
| 2019 | 0.00% | 0.00% | -0.06x | 0.00x | $-22.03 Million |
| 2020 | -89.70% | 0.00% | 0.00x | 1.45x | $-35.36 Million |
| 2021 | -126.45% | 0.00% | 0.00x | 1.51x | $-26.39 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.43 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.71 Million |
| 2024 | 0.00% | 1369.02% | 0.46x | 0.00x | $12.40 Million |
Industry Comparison
This section compares Brainstorm Cell Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Brainstorm Cell Therapeutics Inc (BCLI) | $822.00K | -49.00% | 0.06x | $7.28 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modula… Read more